Drug Trial Radar · NCT06253130
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
156
Planned (sponsor's estimate)
Start
Dec 11, 2023
Primary completion
Jun 1, 2027
Study completion Dec 1, 2027
Sponsor
- Lead sponsor
- Eikon TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Impact Therapeutics, Inc.
- First posted
- Feb 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
IMP1734Drug
PARP1 selective inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with adverse events, treatment emergent adverse events or serious adverse eventsTime frame: Consent to 30 + 7 days post last dose of IMP1734
- Maxim Tolerated Dose or Recommended Dose for ExpansionTime frame: DLT period is from the first dose of the study drug until the last day of the first cycle
Locations
57 sites in 8 countries. Site status is shown where the registry gives one.
The University of Arizona Cancer Center
Tucson, Arizona · Recruiting
University of Arkansas Winthrop P. Rockefeller Cancer Institute
Little Rock, Arkansas · Recruiting
Hoag Health Center Irvine
Irvine, California · Withdrawn
University California Irvine
Irvine, California · Withdrawn
Sharp Memorial Hospital
San Diego, California · Withdrawn
University of California San Francisco (UCSF)
San Francisco, California · Withdrawn
Sarah Cannon Research Institute Health One
Denver, Colorado · Recruiting
Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut · Recruiting
Advent Health Research Institute
Celebration, Florida · Recruiting
Sylvester Comprehensive Cancer Center
Miami, Florida · Recruiting
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Henry Ford Health
Detroit, Michigan · Recruiting
University of Minnesota-Clinical Research Unit
Minneapolis, Minnesota · Recruiting
Washington University - Siteman Cancer Center
St Louis, Missouri · Withdrawn
John Theurer Cancer Center
Hackensack, New Jersey · Withdrawn
Cayuga Medical Center
Ithaca, New York · Withdrawn
Lifespan Cancer Institute
Providence, Rhode Island · Recruiting
Medical University of South Carolina (MUSC) - Hollings CC
Charleston, South Carolina · Recruiting
West Cancer Center & Research Institute
Germantown, Tennessee · Recruiting
Sarah Cannon Research Institue Oncology
Nashville, Tennessee · Recruiting
START - South Texas Accelerated Research Therapeutics
San Antonio, Texas · Withdrawn
START Mountain Region
West Valley City, Utah · Withdrawn
Scientia Clinical Research Ltd
Randwick, New South Wales, Australia · Active not recruiting
Mater Cancer Care Centre, Mater Misericordiae Limited
South Brisbane, Queensland, Australia · Recruiting
Gold Coast Private Hospital
Southport, Queensland, Australia · Not yet recruiting
Macquarie University
Sydney, Queensland, Australia · Recruiting
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia · Recruiting
Peninsula and south eastern haematology and oncology group
Frankston, Victoria, Australia · Recruiting
Cross Cancer Institute
Edmonton, Alberta, Canada · Recruiting
Sunnybrook Research Institute
Toronto, Ontario, Canada · Recruiting
Princess Margaret Cancer Centre-University Health Network
Toronto, Ontario, Canada · Recruiting
Chongqing University Cancer Hospital
Chongqing, China · Recruiting
Fujian Cancer Hospital
Fuzhou, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Recruiting
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.